无并发症金黄色葡萄球菌菌血症七天与十四天抗生素治疗疗效比较(SAB7):随机对照试验研究方案
SAB7为随机、非盲、非劣效、多中心干预研究,计划在丹麦十家中心纳入284例无并发症金黄色葡萄球菌菌血症患者,1:1随机分为第7天停药组与持续至14天组,主要终点为90天无临床或微生物学治疗失败或复发的生存率,非劣效界值10个百分点。
要点
- 无并发症SAB患者第7天停用抗生素是否非劣于14天方案尚需验证。
- 主要终点为90天无临床或微生物学失败或复发的生存率,非劣效界值10个百分点。
- 计划在丹麦十家中心纳入284例,随访6个月并记录不良事件。
核心结论
- SAB7将确定无并发症SAB患者7天抗生素治疗是否不劣于14天治疗且安全。
- 研究结果可能为优化SAB管理提供重要信息,并可能修正当前治疗推荐。
研究设计与样本
- 随机、非盲、非劣效、多中心干预研究,计划在丹麦十家中心纳入284例无并发症SAB患者。
- 患者已接受7天方案批准的抗生素后1:1随机分为第7天停药组或持续抗生素治疗至总共14天组。
- 主要排除标准包括存在继发深部感染、持续性菌血症和植入装置等复杂性SAB征象。
- 患者随访6个月,进行临床检查、连续血液检测并记录不良事件。
主要发现
- 主要终点为90天无临床或微生物学治疗失败或复发的生存率,采用10个百分点的非劣效界值进行统计检验。
- 次要结局包括严重不良效应(尤其是艰难梭菌继发感染)的患病率、全因死亡率以及公共卫生相关费用。
关键数值与推荐
- 当前指南推荐SAB抗生素治疗至少14天,以尽量减少继发深部感染和复发风险,但支持该推荐的证据仍 scarce。
- 无并发症SAB患者已知复发和死亡风险低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Staphylococcus aureus bacteremia (SAB) is frequently encountered in the hospital setting, and current guidelines recommend at least 14 days of antibiotic treatment for SAB in order to minimize risks of secondary deep infections and relapse. However, evidence to support these treatment recommendations remains scarce. Patients with uncomplicated SAB are known to have a low of risk of recurrence and death. Reducing treatment length in uncomplicated SAB would reduce the total consumption of antibiotics, duration of hospital admission, and potentially the risk of adverse events. With SAB7 we seek to determine if 7 days of antibiotic treatment in patients with uncomplicated SAB is non-inferior to 14 days of treatment. METHODS/DESIGN: The study is designed as a randomized, non-blinded, non-inferiority, multicenter interventional study. Primary measure of outcome will be 90-day survival without clinical or microbiological failure to treatment or relapse. Secondary outcomes include the prevalence of severe adverse effects, in particular secondary infection with Clostridium difficile, all-cause mortality, as well as public health related costs. Patients identified with uncomplicated SAB who have received 7 days of protocol-approved antibiotics will be eligible for inclusion and randomized 1:1 in two parallel arms to either (i) discontinue antibiotic treatment at day 7 or (ii) to continue antibiotic treatment for a total of 14 days. Main exclusion criteria include signs of complicated SAB, such as the presence of secondary deep infections, persistent bacteremia, and implantable devices. Patients are followed for 6 months with clinical examinations, consecutive blood tests, and registration of adverse events. A total of 284 patients are to be included at ten centers across Denmark. The primary endpoint will be tested with a statistical non-inferiority margin of 10 percentage points. DISCUSSION: SAB 7 will determine if 7 days of antibiotic treatment in patients with uncomplicated SAB is sufficient and safe. Results of the study will provide important knowledge on optimized SAB management and could potentially modify the current treatment recommendations. TRIAL REGISTRATION: ClinicalTrails.gov, H-17027414 . Registered on May 2, 2018. The Danish Medicines Agency (EudraCT), 2017-003529-13. Registered on October 30, 2017.
引用
- Thorlacius-Ussing L, Andersen CØ, Frimodt-Møller N, et al. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial. Trials. 2019. PMID: 31046810. doi:10.1186/s13063-019-3357-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。